Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011:493:469-85.
doi: 10.1016/B978-0-12-381274-2.00018-2.

Advancing fragment binders to lead-like compounds using ligand and protein-based NMR spectroscopy

Affiliations

Advancing fragment binders to lead-like compounds using ligand and protein-based NMR spectroscopy

Till Maurer. Methods Enzymol. 2011.

Abstract

The application of NMR in fragment-based lead discovery (FBLD) has quickly developed from a sensitive method for the identification of low-affinity binders to an important tool in the hit-to-lead process. NMR can play a constructive role in the process from identifying those fragments with the best potential toward a biochemically active compound to developing them into molecules with high affinity and selectivity to a given target protein. NMR hit-to-lead involves revising the lead identification process at the beginning of a fragment-based drug discovery project, the primary screen, and also looking toward protein-detected NMR methods in advancing compounds from fragment hit into and through fragment hit-to-lead. With the development of higher sensitivity cold NMR probes, ligand-based NMR methods can be successfully applied to a majority of projects found in a pharmaceutical pipeline. Having matured from the original concepts such as SAR by NMR (Shuker, S. B., Hajduk, P. J., Meadows, R. P., Fesik, S. W. (1996) Discovering high-affinity ligands for proteins: SAR by NMR. Science274 (5292), 1531-1534.), projects that base their lead matter on fragment hits are close to or already in the clinic (Woodhead, A. J., Angove, H., Carr, M. G., Chessari, G., Congreve, M., Coyle, J. E., Cosme, J., Graham, B., Day, P. J., Downham, R., Fazal, L., Feltell, R., et al. (2010) discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design. J. Med. Chem.53, 5956-5969, Chessari, G., and Woodhead, A. J. (2009). From fragment to clinical candidate: A historical perspective. Drug Discov. Today14 (13-14), 668-675.). Generating new ideas toward new binding modes and mechanisms of action as well as new intellectual property will be the standard by which the success of FBLD will need to be measured. A strategy outlining the various steps involved in NMR hit-to-lead is provided. By means of a specific example, the workflow is described to guide the reader through the experimental setup.

PubMed Disclaimer

Similar articles

Cited by

  • Targeting protein-protein interactions as an anticancer strategy.
    Ivanov AA, Khuri FR, Fu H. Ivanov AA, et al. Trends Pharmacol Sci. 2013 Jul;34(7):393-400. doi: 10.1016/j.tips.2013.04.007. Epub 2013 May 29. Trends Pharmacol Sci. 2013. PMID: 23725674 Free PMC article. Review.
  • Medicinal chemistry for 2020.
    Satyanarayanajois SD, Hill RA. Satyanarayanajois SD, et al. Future Med Chem. 2011 Oct;3(14):1765-86. doi: 10.4155/fmc.11.135. Future Med Chem. 2011. PMID: 22004084 Free PMC article.

LinkOut - more resources